Study found that patients who received sotrovimab showed an 85 percent reduction in their risk for hospitalization or death versus placebo
Combination Monoclonal Antibody Treatment Authorized for COVID-19
EUA issued for combination of bamlanivimab and etesevimab in patients with mild-to-moderate COVID-19 at high risk for disease progression